FDA Update: Agency Expands Use of Evkeeva to Treat Young Children With HoFH

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Evkeeva (evinacumab-dgnb) to treat young children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH).

The drug was initially approved by the FDA in February 2021 as an adjunct to other LDL-C lowering therapies to treat adult and pediatric patients aged 12 years and older with HoFH.

Access ACC's online course, Familial Hypercholesterolemia: Improving Detection to Accelerate Treatment, and CardioSmart patient resources for more information on FH.

Clinical Topics: Congenital Heart Disease and Pediatric Cardiology, Dyslipidemia, CHD and Pediatrics and Prevention, Homozygous Familial Hypercholesterolemia, Lipid Metabolism, Primary Hyperlipidemia

Keywords: ACC Advocacy, Child, Child, Preschool, Adult, Hypercholesterolemia, Pharmaceutical Preparations, United States Food and Drug Administration, Hyperlipoproteinemia Type II

< Back to Listings